EGFR and Patent ductus arteriosus: While KRAS/NRAS mutations are well known to predict a lack of efficacy from anti-EGFR antibodies in colorectal cancers [37,38], studies investigating the addition of the EGFR TKI erlotinib to chemotherapy in advanced BTC and PDA suggested a similar pattern [10,11,16].